Invivogen: Ruxolitinib

Lab Reagents

Human IgG antibody Laboratories manufactures the invivogen: ruxolitinib reagents distributed by Genprice. The Invivogen: Ruxolitinib reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact InVivoGen. Other Invivogen: products are available in stock. Specificity: Invivogen: Category: Ruxolitinib

Chemicals information

Ruxolitinib (INCB018424)

A3012-5.1 10 mM (in 1mL DMSO)
EUR 131
Description: Ruxolitinib dihydrochloride is a specific inhibitor of Janus-associated kinase (JAK1 and JAK2). Ruxolitinib is a small molecular with the formula of C17H21N6O4Pand Molecular Weight of 404.

Ruxolitinib (INCB018424)

A3012-S Evaluation Sample
EUR 81
Description: Ruxolitinib dihydrochloride is a specific inhibitor of Janus-associated kinase (JAK1 and JAK2). Ruxolitinib is a small molecular with the formula of C17H21N6O4Pand Molecular Weight of 404.

Ruxolitinib (phosphate)

HY-50858 5mg
EUR 119

Ruxolitinib (sulfate)

HY-50859 100mg
EUR 519

Ruxolitinib, Free base

2139-100 Ask for price

Ruxolitinib, Free base

2139-25
EUR 533

Ruxolitinib, Free base

2139-5
EUR 207

S-Ruxolitinib (INCB018424)

A4149-1 1 mg
EUR 231
Description: S-Ruxolitinib is the chirality of INCB018424, is a potent and selective small-molecule Janus kinase 1 (JAK1) and JAK2 inhibitor. It was initially developed to target the constitutive activation of the JAK-STAT pathway.

S-Ruxolitinib (INCB018424)

A4149-5 5 mg
EUR 429
Description: S-Ruxolitinib is the chirality of INCB018424, is a potent and selective small-molecule Janus kinase 1 (JAK1) and JAK2 inhibitor. It was initially developed to target the constitutive activation of the JAK-STAT pathway.

S-Ruxolitinib (INCB018424)

A4149-5.1 10 mM (in 1mL DMSO)
EUR 306
Description: S-Ruxolitinib is the chirality of INCB018424, is a potent and selective small-molecule Janus kinase 1 (JAK1) and JAK2 inhibitor. It was initially developed to target the constitutive activation of the JAK-STAT pathway.

Ruxolitinib (S enantiomer)

HY-50856A 5mg
EUR 340

Ruxolitinib (JAK kinase inhibitor)

SIH-509-25MG 25 mg
EUR 625
  • Ruxolitinib is a Janus-associated kinases (JAK) inhibitor, which specifically inhibits JAK1 and JAK3. JAKs are known to active the signaling of certain growth factor receptors and cytokines.
Description: The substance Ruxolitinib is a jak kinase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is off-white solid which is soluble in DMSO (25 mg/ml) or EtOH (~15 mg/ml).

Ruxolitinib (JAK kinase inhibitor)

SIH-509-5MG 5 mg
EUR 238
  • Ruxolitinib is a Janus-associated kinases (JAK) inhibitor, which specifically inhibits JAK1 and JAK3. JAKs are known to active the signaling of certain growth factor receptors and cytokines.
Description: The substance Ruxolitinib is a jak kinase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is off-white solid which is soluble in DMSO (25 mg/ml) or EtOH (~15 mg/ml).